title: A phase II study of a 21 day continuous infusion schedule with epirubicin in advanced gastric cancer.
authors.affiliation: Department of Internal Medicine, University Hospital Groningen, The Netherlands.
authors.forename: E G
authors.initials: EG
authors.lastname: De Vries
authors.forename: A G
authors.initials: AG
authors.lastname: Nanninga
authors.forename: J
authors.initials: J
authors.lastname: Greidanus
authors.forename: E T
authors.initials: ET
authors.lastname: Oremus
authors.forename: R C
authors.initials: RC
authors.lastname: Verschueren
authors.forename: N H
authors.initials: NH
authors.lastname: Mulder
authors.forename: D T
authors.initials: DT
authors.lastname: Sleijfer
authors.forename: P H
authors.initials: PH
authors.lastname: Willemse
mesh_terms: D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D015251:Epirubicin